Replies to post #5228 on International Stem Cell Corp. (ISCO)

[MinnieM]

$ISCO News, SEC filings, Business Plan, and misc:

SEC filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001355790&owner=include&count=40

OTCQB: http://www.otcmarkets.com/stock/ISCO/quote

Press Releases: http://www.internationalstemcell.com/Press_Releases

Recent News: http://finance.yahoo.com/q/h?s=ISCO+Headlines

They are expecting to file an IND for Parkinson’s disease with the FDA in late 2014 or early 2015. That will gain them a lot of new attention.

Having two subsidiaries bringing in revenues to offset the need for dilution while working on therapies is an excellent thing. Plus, one or both of the subsidiaries could end up huge down the road. I really like the way they have set themselves up for future growth. As with any stock in this sector, there are still risks. I only invest that which I can afford to lose. However, they are very unusual since most don't have any revenues at this stage of development.

From the ISCO website: http://www.b2i.us/profiles/investor/fullpage.asp?BzID=1468&to=cp&Nav=0&LangID=1&s=396&ID=14259

Business Model

International Stem Cell Corporation (ISCO) operates under a novel business model for the biotechnology industry. This model comprises subsidiary business units that generate revenue from the sale of products developed from scientific discoveries made by ISCO. Not only is this model self-sustaining with the revenues used to support further scientific research and development, but it also provides practical, short-term applications of the core technologies.

Therapeutic Programs
http://www.internationalstemcell.com/Therapeutic_Programs

Lifeline Skin Care (LSC)
http://www.lifelineskincare.com/

Lifeline Cell Technology (LCT)
http://www.lifelinecelltech.com/

Intellectual Property
http://www.internationalstemcell.com/Intellectual_Property

Scientific Publications
http://www.internationalstemcell.com/Scientific_Publications

Management: http://www.internationalstemcell.com/Management

Company Address:
Corporate Headquarters
5950 Priestly Drive
Carlsbad, CA 92008
Phone: [phone]
Fax: [phone]

~~~~~~~~~~

The following is of particular importance:

International Stem Cell Corporation Enters Into Clinical Research Agreement for Parkinson's Disease Program

http://finance.yahoo.com/news/international-stem-cell-corporation-enters-123000045.html

CARLSBAD, CA--(Marketwired - Aug 21, 2013) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell-based therapies, announced today that it has entered into a master clinical research agreement with Duke University to conduct clinical trials research in Parkinson's disease using ISCO's innovative neural stem cell product.

Mark Stacy, M.D., Vice Dean for Clinical Research, Neurology at Duke University School of Medicine and an internationally recognized leader in the field of Movement Disorders, including Parkinson's disease, will be the study's principal investigator. The research will be coordinated by the Duke Clinical Research Institute (DCRI), the world's largest academic clinical research organization, which is internationally recognized for conducting groundbreaking clinical trials.

"We are pleased to have the opportunity to conduct the clinical trials related to ISCO's investigational stem cell therapy in Parkinson's disease patients," said Stacy. "Duke has an exceptional clinical trials team and we look forward to characterizing and understanding the safety and efficacy profile of this agent in the clinical trials setting."

"We're tremendously excited to be working with such a world-class clinical research organization as Duke University," commented Dr. Ruslan Semechkin, Vice President of Research and Development at International Stem Cell Corporation. "Dr. Stacy and his team have made numerous significant contributions in the field of Parkinson's disease research which together with Duke's extensive clinical expertise in cell therapy clinical trials and the extensive patient population, gives us an outstanding opportunity to evaluate our revolutionary stem cell therapy."

Stacy has extensive clinical trials experience, primarily involving neuro-protective and neuro-regenerative therapies and developing biomarkers for early diagnosis in Parkinson's disease. He has published more than 100 peer-reviewed scientific papers in the field and has served as an advisor to a number of companies. He has participated in more than 100 clinical trials.

ISCO's Parkinson's disease program uses human parthenogenetic neural stem cells (hPNSC), a novel therapeutic cellular product derived from the company's proprietary histocompatible human pluripotent stem cells. The hPNSC are self-renewing mulitpotent cells that are precursors for the major cells of the central nervous system. The ability of hPNSC to (1) differentiate into dopaminergic neurons and (2) express neurotrophic factors such as glial derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) to protect the nigrostriatal system, offers a new and revolutionary opportunity for the treatment of Parkinson's disease, especially in cases where current dopamine-replacement approaches fail to adequately control the symptoms.